Clinical Trials | May 20, 2023
Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
It is developing the drug candidate to potentially treat immunological diseases
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Subscribe To Our Newsletter & Stay Updated
